Chemical Carcinogenesis Denis M. Grant 4.1 Introduction and Historical Perspective 4.2 Biology of Chemical Carcinogenesis 4.2.1 Tumor Initiation, Promotion, and Progression 4.2.2 Genetic Instability and the Hallmarks of Cancer 4.2.3…
Imaging in Oncology David A. Jaffray 14.1 Introduction 14.2 General Concepts Relating to Cancer Imaging 14.3 Imaging Technologies 14.3.1 X-ray–Based Systems: Radiography and Computed Tomography 14.3.2 Magnetic Resonance Imaging 14.3.3…
Oncogenic Viruses and Tumor Viruses Fei-Fei Liu and Christopher D. Richardson 6.1 Introduction 6.2 DNA Tumor Viruses 6.2.1 Polyomaviruses 6.2.2 Human Adenoviruses 6.2.3 Human Papillomaviruses 6.2.4 Epstein-Barr Virus 6.2.5 Hepatitis…
Benign tumors Papillary adenoma Renal oncocytoma Metanephric adenoma Metanephric adenofibroma Malignant tumors Clear cell renal cell carcinoma Multilocular clear cell renal cell neoplasm of low malignant potential Papillary renal cell…
Features suggestive of hereditary RCC Family history of RCC or confirmed syndrome Bilaterality, multifocality, early age of onset Histology: non-clear cell with unusual features, e.g., papillary type II morphology with…
Symptoms or signs Skinner n = 309 (%) Gibbons n = 110 (%) Jayson N = 131 (%) Gupta N = 811 group 1 group 4 Hematuria 59 37 24 29 39 Abdominal or flank mass 45 21…
Toxicity Sunitinib Sorafenib Pazopanib Axitinib All grade % Grade 3/4 % All grade % Grade 3/4 % All grade % Grade 3/4 % All grade % Grade 3/4 % General…
Type Prevalence/histology Genetic alterations Pertinent molecular pathways Papillary RCC type 1 and 2 10–15 % Type 1 with small cells and little cytoplasm; basophilic Type 2 with large cells and…
Kd References PD-1:pembrolizumab 0.028 nM (Hamid [89] #114) * while Kd 28 pM, 50 % effective binding concentration of pembrolizumab was 0.1–0.3 nM PD-1:nivolumab 2.6 nM (Brahmer [81] #48)…
